BRCA2 and neoplasm: In particular, we found that among four HGOC patients, who underwent upfront germline testing and subsequent tumour sequencing, one showed discordant results, with a germline one-base deletion at a homopolymeric site of BRCA2 that was not identified by the ION Reporter software at tumour testing.